Laura Chico Analyst PerformanceManaging Director, Equity Research at WedbushLaura Chico is a stock analyst at Wedbush focused in the healthcare sector, covering 36 publicly traded companies. Over the past year, Laura Chico has issued 91 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Laura Chico's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Chico's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings136 Last 8 YearsBuy Recommendations74.26% 101 Buy RatingsCompanies Covered36 Unique Companies Ratings Distribution136RatingsDistribution of strong buy, buy, hold, and sell ratings by Laura Chico.RatingPercentageCount Strong Buy0.7%1 ratings Buy73.5%100 ratings Hold21.3%29 ratings Sell4.4%6 ratingsOut of 136 total stock ratings issued by Laura Chico at Wedbush, the majority (73.5%) have been Buy recommendations, followed by 21.3% Hold, 4.4% Sell, and 0.7% Strong Buy.Best & Worst CallsBest Call0000.0%OVIDMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%VTLDec 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ88.9% of companies on NASDAQ32 companiesNYSE8.3% of companies on NYSE3 companiesOTCMKTS2.8% of companies on OTCMKTS1 companyLaura Chico, an analyst at Wedbush, currently covers 36 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare34 companies94.4%Consumer Discretionary1 company2.8%Technology1 company2.8%Laura Chico of Wedbush specializes in stock coverage within the Healthcare sector, with additional focus on Consumer Discretionary and Technology companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY26 companies72.2%PHARMACEUTICALS8 companies22.2%HOUSEHOLD DURABLES1 company2.8%SOFTWARE1 company2.8% About Laura ChicoLaura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease. Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.Follow on LinkedIn Laura Chico's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsNBIXNeurocrine Biosciences8/3/2026Boost Price Target$166.80$194.00Outperform$0.0000.00% ROIBIIBBiogen7/30/2026Boost Price Target$206.17$215.00Neutral$0.0000.00% ROICLYMClimb Bio7/27/2026Boost Price Target$12.84$20.00Outperform$0.0000.00% ROIDNLIDenali Therapeutics7/13/2026Reiterated Rating$25.64$26.00Outperform$0.0000.00% ROIBIIBBiogen7/13/2026Reiterated Rating$202.06$201.00Neutral$0.0000.00% ROIVERAVera Therapeutics7/8/2026Boost Price Target$42.96$43.00Neutral$0.0000.00% ROIVRDNViridian Therapeutics6/30/2026Boost Price Target$18.79$43.00Outperform$0.0000.00% ROITVTXTravere Therapeutics6/22/2026Boost Price Target$55.15$61.00Outperform$0.0000.00% ROICLYMClimb Bio6/12/2026Reiterated Rating$11.12$17.00Outperform$0.0000.00% ROITVTXTravere Therapeutics6/3/2026Reiterated Rating$42.94$55.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. JBIOJade Biosciences6/2/2026Boost Price Target$18.59$45.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines6/2/2026Lower Price Target$303.77$162.00Underperform$0.0000.00% ROIEWTXEdgewise Therapeutics6/1/2026Boost Price Target$40.26$52.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics5/18/2026Lower Price Target$3.58$12.00Outperform$0.0000.00% ROIANROAlto Neuroscience5/14/2026Boost Price Target$22.94$24.00Neutral$0.0000.00% ROIPEPGPepGen5/13/2026Lower Price Target$1.61$4.00Outperform$0.0000.00% ROISLDBSolid Biosciences5/13/2026Lower Price Target$7.78$16.00Outperform$0.0000.00% ROIJBIOJade Biosciences5/11/2026Boost Price Target$25.81$34.00Outperform$0.0000.00% ROICLYMClimb Bio5/8/2026Boost Price Target$11.94$17.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines5/8/2026Boost Price Target$334.73$166.00Underperform$0.0000.00% ROIDNLIDenali Therapeutics5/8/2026Lower Price Target$19.89$23.00Outperform$0.0000.00% ROIBCRXBioCryst Pharmaceuticals5/7/2026Lower Price Target$8.66$21.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics5/6/2026Boost Price Target$90.24$105.00Outperform$0.0000.00% ROIRAREUltragenyx Pharmaceutical5/6/2026Lower Price Target$25.01$26.00Neutral$0.0000.00% ROINBIXNeurocrine Biosciences5/6/2026Boost Price Target$135.06$176.00Outperform$0.0000.00% ROITVTXTravere Therapeutics5/5/2026Boost Price Target$44.91$55.00Outperform$0.0000.00% ROISIONSionna Therapeutics5/5/2026Initiated Coverage$40.45$53.00Outperform$0.0000.00% ROISIONSionna Therapeutics5/4/2026Upgrade$40.97Strong-Buy$0.0000.00% ROIBIIBBiogen4/30/2026Boost Price Target$194.38$196.00Neutral$0.0000.00% ROIOVIDOvid Therapeutics4/15/2026Reiterated Rating$2.96$7.00Outperform$0.0000.00% ROITVTXTravere Therapeutics4/14/2026Boost Price Target$41.18$44.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics4/8/2026Lower Price Target$13.96$31.00Outperform$0.0000.00% ROIPHVSPharvaris4/7/2026Boost Price Target$28.37$42.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences4/7/2026Boost Price Target$132.48$166.00Outperform$0.0000.00% ROIANROAlto Neuroscience4/2/2026Lower Price Target$20.41$21.00Neutral$0.0000.00% ROIVRDNViridian Therapeutics3/31/2026Lower Price Target$18.82$37.00Outperform$0.0000.00% ROIPEPGPepGen3/31/2026Lower Price Target$1.44$5.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics3/20/2026Boost Price Target$4.47$13.00Outperform$0.0000.00% ROIOVIDOvid Therapeutics3/20/2026Boost Price Target$2.30$7.00Outperform$0.0000.00% ROIEWTXEdgewise Therapeutics3/17/2026Reiterated Rating$29.78$32.00Outperform$0.0000.00% ROIALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.See the 5 stocks to avoidSTOKStoke Therapeutics3/17/2026Boost Price Target$33.96$38.00Outperform$0.0000.00% ROIANROAlto Neuroscience3/17/2026Boost Price Target$24.27$22.00Neutral$0.0000.00% ROIXENEXenon Pharmaceuticals3/16/2026Lower Price Target$55.23$63.00Outperform$0.0000.00% ROIMAZEMaze Therapeutics3/16/2026Boost Price Target$50.21$58.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics3/11/2026Reiterated Rating$29.19$44.00Outperform$0.0000.00% ROISLDBSolid Biosciences3/11/2026Reiterated Rating$8.18$14.00Outperform$0.0000.00% ROIXENEXenon Pharmaceuticals3/10/2026Boost Price Target$62.76$64.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics3/10/2026Boost Price Target$79.23$80.00Outperform$0.0000.00% ROIJBIOJade Biosciences3/9/2026Reiterated Rating$14.05$24.00Outperform$0.0000.00% ROICLYMClimb Bio3/5/2026Initiated Coverage$7.28$12.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics3/3/2026Boost Price Target$5.36$12.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics2/25/2026Reiterated Rating$3.69$11.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals2/25/2026Lower Price Target$22.13$18.00Neutral$0.0000.00% ROIGOSSGossamer Bio2/24/2026Reiterated Rating$0.42$1.00Neutral$0.0000.00% ROIARDXArdelyx2/23/2026Reiterated Rating$5.73$19.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines2/20/2026Boost Price Target$331.61$130.00Underperform$0.0000.00% ROIRAREUltragenyx Pharmaceutical2/17/2026Reiterated Rating$20.66$25.00Neutral$0.0000.00% ROINBIXNeurocrine Biosciences2/12/2026Boost Price Target$126.00$151.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics2/11/2026Boost Price Target$49.44$55.00Outperform$0.0000.00% ROIBIIBBiogen2/9/2026Boost Price Target$201.18$187.00Neutral$0.0000.00% ROIARDXArdelyx1/21/2026Boost Price Target$7.76$19.00Outperform$0.0000.00% ROISTOKStoke Therapeutics1/12/2026Boost Price Target$32.85$36.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines1/12/2026Boost Price Target$288.45$95.00Underperform$0.0000.00% ROIDNTHDianthus Therapeutics12/22/2025Reiterated Rating$42.44$46.00Outperform$0.0000.00% ROIVERAVera Therapeutics12/11/2025Boost Price Target$44.34$33.00Neutral$0.0000.00% ROIDNLIDenali Therapeutics12/11/2025Lower Price Target$17.49$30.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics12/10/2025Boost Price Target$31.80$47.00Outperform$0.0000.00% ROIDNLIDenali Therapeutics12/5/2025Boost Price Target$20.11$31.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines12/5/2025Reiterated Rating$189.97$83.00Underperform$0.0000.00% ROIARDXArdelyx11/25/2025Downgrade$5.50Hold$0.0000.00% ROIPHVSPharvaris11/13/2025Boost Price Target$26.13$30.00Outperform$0.0000.00% ROIMAZEMaze Therapeutics11/7/2025Boost Price Target$29.21$36.00Outperform$0.0000.00% ROIEWTXEdgewise Therapeutics11/7/2025Lower Price Target$17.58$32.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics11/6/2025Boost Price Target$33.73$46.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines11/6/2025Boost Price Target$164.64$77.00Underperform$0.0000.00% ROISTOKStoke Therapeutics11/5/2025Boost Price Target$21.20$32.00Outperform$0.0000.00% ROIATXSAstria Therapeutics10/15/2025Set Price Target$11.61$13.00Neutral$0.0000.00% ROIATXSAstria Therapeutics10/15/2025Downgrade$11.92$13.00Neutral$0.0000.00% ROILRMRLarimar Therapeutics9/30/2025Lower Price Target$3.38$11.00Outperform$0.0000.00% ROIPEPGPepGen9/25/2025Boost Price Target$5.97$9.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences9/22/2025Reiterated Rating$146.62Outperform$0.0000.00% ROIDNTHDianthus Therapeutics9/12/2025Boost Price Target$37.86$44.00Outperform$0.0000.00% ROITRMLTourmaline Bio9/9/2025Downgrade$30.18$48.00Neutral$0.0000.00% ROIDNTHDianthus Therapeutics8/21/2025Boost Price Target$23.72$42.00Outperform$0.0000.00% ROIJBIOJade Biosciences8/14/2025Boost Price Target$7.03$18.00Outperform$0.0000.00% ROISLDBSolid Biosciences8/13/2025Lower Price Target$6.15$14.00Outperform$0.0000.00% ROISTOKStoke Therapeutics8/13/2025Boost Price Target$15.66$22.00Outperform$0.0000.00% ROIXENEXenon Pharmaceuticals8/12/2025Boost Price Target$36.10$43.00Outperform$0.0000.00% ROITVTXTravere Therapeutics8/7/2025Boost Price Target$17.24$32.00Outperform$0.0000.00% ROIGOSSGossamer Bio8/6/2025Boost Price Target$1.97$5.00Outperform$0.0000.00% ROIBuy this stock today (Ad)Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.Get the name, ticker, and full Hotlist before markets openARDXArdelyx8/5/2025Reiterated Rating$5.08$14.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences7/31/2025Boost Price Target$136.76$141.00Outperform$000.0000.00% ROIRAREUltragenyx Pharmaceutical7/14/2025Lower Price Target$29.51$34.00Neutral$00.0000.00% ROIMAZEMaze Therapeutics7/8/2025Initiated Coverage$12.12$17.00Outperform$00.0000.00% ROILRMRLarimar Therapeutics6/24/2025Lower Price Target$2.76$15.00Outperform$0.0000.00% ROILENLennar6/18/2025Reiterated Rating$105.15$130.00Neutral$00.0000.00% ROIBIIBBiogen6/12/2025Reiterated Rating$132.63$121.00Neutral$000.0000.00% ROIPHVSPharvaris6/5/2025Reiterated Rating$16.88$27.00Outperform$00.0000.00% ROIVIGLVigil Neuroscience5/22/2025Downgrade$2.31$8.00Hold$0.0000.00% ROITVTXTravere Therapeutics5/16/2025Reiterated Rating$17.51$30.00Outperform$00.0000.00% ROIGOSSGossamer Bio5/16/2025Reiterated Rating$1.08$4.00Outperform$0.0000.00% ROIANROAlto Neuroscience5/15/2025Reiterated Rating$2.26$4.00Neutral$00.0000.00% ROIDNLIDenali Therapeutics5/7/2025Lower Price Target$14.02$30.00Outperform$00.0000.00% ROIVERAVera Therapeutics5/7/2025Lower Price Target$22.33$26.00Neutral$00.0000.00% ROIVIGLVigil Neuroscience5/5/2025Reiterated Rating$2.85$13.00Outperform$0.0000.00% ROITVTXTravere Therapeutics5/2/2025Reiterated Rating$20.56$30.00Outperform$00.0000.00% ROIEWTXEdgewise Therapeutics4/21/2025Reiterated Rating$13.67$43.00Outperform$00.0000.00% ROIVIGLVigil Neuroscience3/14/2025Lower Price Target$2.15$13.00Outperform$0.0000.00% ROIGOSSGossamer Bio3/14/2025Reiterated Rating$1.35$4.00Outperform$0.0000.00% ROIOVIDOvid Therapeutics3/12/2025Reiterated Rating$0.49$3.00Outperform$0.0000.00% ROIATXSAstria Therapeutics3/12/2025Reiterated Rating$6.47$28.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics3/12/2025Reiterated Rating$22.69$36.00Outperform$00.0000.00% ROITRMLTourmaline Bio3/6/2025Initiated Coverage$12.90$42.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals3/3/2025Lower Price Target$25.15$29.00Neutral$00.0000.00% ROINBIXNeurocrine Biosciences2/7/2025Lower Price Target$121.12$147.00Outperform$000.0000.00% ROIRAREUltragenyx Pharmaceutical1/13/2025Reiterated Rating$41.84$48.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
